BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President...
BioMarin
BioMarin Announces New R&D and Business Development Leadership
Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.D., Will Retire After 15 Years at Company James Sabry,...
